Tg Therapeutics (TGTX)

Jan 13, 2025, 11:38 PM EST - 4 days ago

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

Jan 9, 2025, 7:30 AM EST - 8 days ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 7:36 AM EST - 6 weeks ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

Nov 29, 2024, 8:00 AM EST - 7 weeks ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Nov 21, 2024, 6:00 AM EST - 2 months ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 5, 2024, 1:50 PM EST - 2 months ago

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

Nov 4, 2024, 8:27 PM EST - 2 months ago

TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell

Nov 4, 2024, 11:16 AM EST - 2 months ago

TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 9:00 AM EST - 2 months ago

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

Nov 1, 2024, 8:06 AM EDT - 2 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Sep 22, 2024, 8:17 AM EDT - 4 months ago

TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

Sep 18, 2024, 7:15 AM EDT - 4 months ago

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Sep 18, 2024, 7:00 AM EDT - 4 months ago

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Sep 5, 2024, 7:30 AM EDT - 4 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Aug 7, 2024, 4:59 AM EDT - 5 months ago

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

Aug 6, 2024, 3:12 PM EDT - 5 months ago

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 9:01 AM EDT - 5 months ago

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Aug 5, 2024, 7:30 AM EDT - 5 months ago

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Jul 30, 2024, 5:00 AM EDT - 6 months ago

TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance

Jun 7, 2024, 7:50 AM EDT - 8 months ago

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 8 months ago

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 31, 2024, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

May 28, 2024, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

May 3, 2024, 9:53 AM EDT - 9 months ago

TG Therapeutics: Less Room For Doubt About Briumvi

May 2, 2024, 10:21 PM EDT - 9 months ago

TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript

May 1, 2024, 9:20 AM EDT - 9 months ago

TG Therapeutics stock just rallied 30%: what happened?

May 1, 2024, 7:00 AM EDT - 9 months ago

TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Apr 30, 2024, 4:55 PM EDT - 9 months ago

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

Apr 18, 2024, 7:30 AM EDT - 9 months ago

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Apr 18, 2024, 7:00 AM EDT - 9 months ago

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

Apr 15, 2024, 7:30 AM EDT - 9 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Apr 12, 2024, 6:17 PM EDT - 10 months ago

TG Therapeutics: BRIUMVI Development Could Lead To Great Results

Mar 8, 2024, 7:30 AM EST - 11 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Mar 1, 2024, 7:30 AM EST - 11 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 28, 2024, 1:14 PM EST - 11 months ago

TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:00 AM EST - 11 months ago

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

Feb 27, 2024, 7:30 AM EST - 11 months ago

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

Feb 26, 2024, 7:00 AM EST - 11 months ago

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

Feb 23, 2024, 7:30 AM EST - 11 months ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

Feb 20, 2024, 7:30 AM EST - 11 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 12, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

DTIL

Feb 8, 2024, 6:48 AM EST - 1 year ago

TG Therapeutics: Inferred Expectations Point To Undervalued Shares

Jan 10, 2024, 10:00 AM EST - 1 year ago

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10, 2024, 9:28 AM EST - 1 year ago

TG Therapeutics stock popped 11% on Wednesday: here's why

Jan 10, 2024, 7:36 AM EST - 1 year ago

TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases

DTIL

Jan 10, 2024, 7:00 AM EST - 1 year ago

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

Jan 9, 2024, 7:00 AM EST - 1 year ago

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

Jan 9, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

DTIL

Jan 5, 2024, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference